3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
8
Recurrence
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Thrombocytosis
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hormone-Resistant Prostate Cancer
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Interventions
Temozolomide
28
Radiosurgery
19
Radiotherapy
17
Bevacizumab
12
Magnetic Resonance Spectroscopy
9
Radiation
6
Erlotinib Hydrochloride
6
Carboplatin
6
Topotecan
5
Nivolumab
5
Mental Status and Dementia Tests
5
Irinotecan
5
Capecitabine
5
pembrolizumab
4
dabrafenib
4
Trastuzumab
4
Sunitinib
4
Pemetrexed
4
Ipilimumab
4
Filgrastim
4
Cyclophosphamide
4
Aminolevulinic Acid
4
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
4
cabozantinib
3
Vorinostat
3
TPI-287
3
Specimen Handling
3
Radiotherapy, Intensity-Modulated
3
Methylphenidate
3
Lomustine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Brain Neoplasms
×
cabazitaxel
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled